Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 243 institutions reported holding it in 13F filings for Q3 2026, worth $3.23B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $2.25B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $84.8K in total
- 1
- 13F holdersQ3 2026, +18 vs. previous quarter
- 243
- 13F valueReported value at the end of Q3 2026
- $3.23B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $247.0M
- −4.3% year over year
- Net income, FY2025
- -$353.0M
- No comparable prior period
- Free cash flow, FY2025
- -$484.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $9.00M
- −65.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $353.0M (142.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 13.2M
- Shares sold short
- Change
- +819.3K
- +6.6% vs. previous
- Days to cover
- 3.56
- At average daily volume
Superinvestors holding RCUS, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding RCUS at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arcus Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 (view filing)5:52 PM ET | Aug 21 | 3 days | Azoy AlexanderChief Accounting Officer | SSale | −2.83K | $30.00 | −$84.8K | −6.7%39.6K after | 10b5-1 |
| Jul 13, 2026 (view filing)5:36 PM ET | Jul 9-10 | 4 days | Jaen Juan C.President | SSale | −68.6K | $29.63 | −$2.03M | −7.7%822.2K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22-24 | 2 days | Jaen Juan C.President | SSale | −31.4K | $27.92 | −$877.5K | −3.4%890.8K after | 4 lots10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Azoy AlexanderChief Accounting Officer | SSale | −2.56K | $25.77 | −$66.0K | −6.1%39.6K after | 10b5-1 |
| May 12, 2026 (view filing) | May 11 | 1 day | Goeltz II Robert C.Chief Financial Officer | SSale | −7.76K | $25.63 | −$199.0K | −8.4%84.2K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Jaen Juan C.President | SSale | −31.8K | $21.41 | −$681.3K | −3.3%922.2K after | 3 lots10b5-1 |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Goeltz II Robert C.Chief Financial Officer | SSale | −6.55K | $23.38 | −$153.2K | −8.8%67.9K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Markus RichardChief Medical Officer | SSale | −9.55K | $22.01 | −$210.1K | −12.7%65.6K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Tang Carolyn C.General Counsel | SSale | −14.5K | $22.01 | −$318.5K | −10.4%124.7K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-18 | 2 days | Azoy AlexanderChief Accounting Officer | SSale | −8.83K | $22.13 | −$195.4K | −32.3%18.5K after | 3 lots10b5-1 |
Top 10 13F holders, Q3 2026
See all 243 holdersThe largest institutional positions in Arcus Biosciences, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | $811.7M | 55.45% | 00.0% | Unchanged |
| BlackRock, Inc. | 16,824,688 | $434.6M | 0.01% | +408,439+2.5% | Added |
| Wellington Management Group LLP | 6,169,222 | $159.4M | 0.03% | +273,774+4.6% | Added |
| State Street Corp | 5,570,292 | $143.9M | 0.00% | −459,192−7.6% | Reduced |
| Vanguard Portfolio Management LLC | 4,440,422 | $114.7M | 0.01% | −35,106−0.8% | Reduced |
| FMR LLC | 4,436,585 | $114.6M | 0.00% | +386,828+9.6% | Added |
| Vanguard Capital Management LLC | 3,931,334 | $101.5M | 0.00% | +42,988+1.1% | Added |
| Citadel Advisors LLC | 2,959,746 | $76.5M | 0.04% | −175,311−5.6% | Reduced |
| Woodline Partners LP | 2,854,798 | $73.7M | 0.22% | −153,000−5.1% | Reduced |
| Janus Henderson Group PLC | 2,538,648 | $65.6M | 0.03% | +2,538,648 | New |
Holders of 5% or more of RCUS
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arcus Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13D/A | 24.70%31.4M shares | −0.90 ppfrom 25.60% | Feb 2, 20218 filings | Aug 7, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 10.40%12.7M shares | +1.00 ppfrom 9.40% | Oct 23, 20244 filings | Jan 8, 2026 | SEC |